Month: October 2026

Press release

Communiqué de presse

Regulated

Syensqo 2027 Financial Calendar

Brussels, Belgium – October 29, 2026 – 8:30 CET  

Syensqo today publishes its 2027 financial calendar and invites the financial community to mark their calendar accordingly.

Event	Date
Full year results 2026	February 25, 2027
First quarter results 2027	April 29, 2027
Ordinary Shareholders’ Meeting	May 4, 2027
Second quarter and Half year results 2027	July 29, 2027
Third quarter results 2027	November 4, 2027

Closed period dates will be provided prior to each earnings season.

Full press release available here.

About Syensqo

Syensqo is a science company developing groundbreaking solutions that enhance the way we live, work, travel and play. Inspired by the scientific councils which Ernest Solvay initiated in 1911, we bring great minds together to push the limits of science and innovation for the benefit of our customers, with a diverse, global team of approximately 13,000 associates in 30 countries.

Our solutions contribute to safer, cleaner, and more sustainable products found in homes, food and consumer goods, planes, cars, batteries, smart devices and healthcare applications. Our innovation power enables us to deliver on the ambition of a circular economy and explore breakthrough technologies that advance humanity.

Learn more at www.syensqo.com.

Contacts

Media Relations media.relations@syensqo.com    Perrine Marchal +32 478 32 62 72 Laetitia Schreiber +32 487 74 38 07

Investors & Analysts investor.relations@syensqo.com Sherief Bakr +44 7920 575 989 Robbin Moore-Randolph +1 470 493 2433 Loïc Flament +32 478 69 74 20 Eva Behaeghe +32 474 49 23 50

Safe harbor
This press release may contain forward-looking information. Forward-looking statements describe expectations, plans, strategies, goals, future events or intentions. The achievement of forward-looking statements contained in this press release is subject to risks and uncertainties relating to a number of factors, including general economic factors, interest rate and foreign currency exchange rate fluctuations, changing market conditions, product competition, the nature of product development, impact of acquisitions and divestitures, restructurings, products withdrawals, regulatory approval processes, all-in scenario of R&I projects and other unusual items. Consequently, actual results or future events may differ materially from those expressed or implied by such forward-looking statements. Should known or unknown risks or uncertainties materialize, or should our assumptions prove inaccurate, actual results could vary materially from those anticipated. The Company undertakes no obligation to publicly update or revise any forward-looking statements.

Useful links

• Earnings materials
• Strategy
• Share information
• Credit information
• Separation documents
• Webcasts, podcasts and presentations
• Annual Integrated Report
• Subscribe to our distribution list

Calendrier financier de Syensqo en 2027

Bruxelles, Belgique – 29 octobre 2026 – 8:30 CET

Syensqo publie aujourd’hui son calendrier financier pour 2027 et invite la communauté financière à noter ces dates.  

Événement	Date
Résultats annuels 2026	25 février 2027
Résultats du premier trimestre 2027	29 avril 2027
Assemblée générale ordinaire des actionnaires	4 mai 2027
Résultats du second trimestre et premier semestre 2027	29 juillet 2027
Résultats du troisième trimestre 2027	4 novembre 2027

Les dates des “périodes calmes” (quiet periods) seront communiquées avant chaque saison de résultats. 

Le communiqué de presse complet est disponible ici.

A propos de Syensqo

Syensqo est une entreprise fondée sur la science qui développe des solutions novatrices permettant d’améliorer notre façon de vivre, de travailler, de voyager et de nous divertir. Inspirés par les congrès scientifiques initiés par Ernest Solvay en 1911, nous réunissons des talents brillants qui repoussent sans cesse les limites de la science et de l’innovation au profit de nos clients, avec près de 13 000 employés.

Nous développons des solutions qui contribuent à offrir des produits plus sûrs, plus propres et plus durables, que l’on retrouve dans l’habitat, l’alimentation, et les biens de consommation, les avions, les voitures, les batteries, les appareils électroniques et les soins de santé. Notre force d’innovation nous permet de concrétiser l’ambition d’une économie circulaire et d’explorer des technologies révolutionnaires qui feront progresser l’humanité.

Plus d’informations sur www.syensqo.com.

Contacts

Media Relations media.relations@syensqo.com    Perrine Marchal +32 478 32 62 72 Laetitia Schreiber +32 487 74 38 07

Investors & Analysts investor.relations@syensqo.com Sherief Bakr +44 7920 575 989 Robbin Moore-Randolph +1 470 493 2433 Loïc Flament +32 478 69 74 20 Eva Behaeghe +32 474 49 23 50

Informations prospectives
Ce communiqué peut contenir des informations prospectives. Les déclarations prospectives décrivent les attentes, plans, stratégies, objectifs, événements futurs ou intentions. La réalisation des déclarations prospectives contenues dans ce communiqué est sujette à des risques et à des incertitudes en raison d’un certain nombre de facteurs, y compris des facteurs économiques d’ordre général, les fluctuations des taux d’intérêt et des taux de change; l’évolution des conditions de marché, la concurrence des produits, la nature du développement d’un produit, l’impact des acquisitions et des désinvestissements, des restructurations, du retrait de certains produits; du processus d’approbation réglementaire, des scénarii globaux des projets de R&I et d’autres éléments inhabituels. Par conséquent, les résultats réels ou événements futurs peuvent différer sensiblement de ceux exprimés ou implicites dans ces déclarations prospectives. Si de tels risques connus ou inconnus ou des incertitudes se concrétisent, ou si nos hypothèses s’avéraient inexactes, les résultats réels pourraient différer considérablement de ceux anticipés. La société ne s’engage nullement à mettre à jour publiquement ses déclarations prospectives.

Liens utiles

• Informations financières
• Stratégie
• Le titre Syensqo
• Obligations et notation financière
• Separation documents
• Webcasts, podcasts et présentations
• Rapport Annuel Intégré
• S’inscrire à notre liste de diffusion

Attachments

• 20261029_Press release_Syensqo 2027 Financial Calendar_EN
• 20261029_Press release_Syensqo 2027 Financial Calendar_FR

KALMAR CORPORATION, TRADE PRESS RELEASE, 29 OCTOBER 2026 AT 9:30 (EET)

Kalmar to supply Tropical Shipping with straddle carrier and reachstacker

Kalmar has secured an order from Tropical Shipping for one Kalmar Hybrid Straddle Carrier equipped with MyKalmar INSIGHT, as well as one Kalmar Reachstacker, for its container terminal in Riviera Beach, Florida, US. The order was booked in Kalmar’s Q3 2026 order intake, with delivery scheduled for Q3 2027.

This order marks a significant milestone for Tropical Shipping as it introduces the first hybrid straddle carrier to its fleet. Addressing rising fuel costs, Tropical Shipping recognized the lifetime cost and efficiency benefits of Kalmar’s hybrid technology. With this addition, Tropical Shipping’s fleet will comprise 29 Kalmar Straddle Carriers and 25 Kalmar Reachstackers.

Douglas Cowper, Vice President of Operations, Tropical Shipping: “We are pleased to expand our fleet with Kalmar’s trusted equipment. Adding our first hybrid straddle carrier supports our goal of managing fuel and maintenance costs effectively over the machine’s lifetime while continuing to deliver reliable service across our terminal operations. This investment also reflects Tropical Shipping’s long-standing commitment to improving efficiency and reducing emissions through practical, proven technologies that support the Caribbean’s supply chain. We selected Kalmar based on our strong partnership, high equipment quality, reliable support, and the advantage of receiving both equipment types from a single partner.”

Troy Thompson, Head of Sales, Horizontal Transportation Americas, Kalmar: “Our long-term partnership with Tropical Shipping continues to grow and strengthen. We are delighted that they have once again placed their trust in Kalmar solutions, including taking delivery of their very first hybrid straddle carrier to enhance operational efficiency and sustainability.”

Further information for the press:

Troy Thompson, Head of Sales, Horizontal Transportation Americas, Kalmar, troy.thompson@kalmarglobal.com 

Annelies Nentjes, Director Marketing and Communications Horizontal Transportation, Kalmar, tel. +31 6 1323 98 46, annelies.nentjes@kalmarglobal.com  

Kalmar (Nasdaq Helsinki: KALMAR) is moving goods in critical supply chains around the world, with the vision to be the forerunner in sustainable material handling equipment and services. The company offers a wide range of industry shaping heavy material handling equipment and services to ports and terminals, distribution centres, manufacturing and heavy logistics. Headquartered in Helsinki, Finland, Kalmar operates globally in over 120 countries and employs approximately 5,300 people. In 2025, the company’s sales totalled approximately EUR 1.7 billion. www.kalmarglobal.com 

Attachment

• Kalmar Hybrid Straddle Carrier

KALMAR CORPORATION, TRADE PRESS RELEASE, 29 OCTOBER 2026 AT 9:20 (EET)

Kalmar secures a significant order from the Port of Virginia for Electric Straddle Carriers

Kalmar has secured a significant order for 10 Kalmar Electric Straddle Carriers from The Port of Virginia®, a deep-water port in the U.S. East Coast. The order was booked in Kalmar’s Q3 2026 order intake, with delivery scheduled to be completed during Q3 of 2027.

The Port of Virginia operates semi-automated container terminals, including Virginia International Gateway (VIG) and Norfolk International Terminals (NIT). The Port of Virginia is deeply committed to sustainable operations and the development of an eco-efficient supply chain and aims to achieve net-zero carbon emissions (Scope 1 & 2) by 2040.

The 10 Kalmar Electric Straddle Carriers will be delivered to NIT, which is the port’s largest terminal. When the delivery is complete, the terminal will have more than 90 semi-automated stacking cranes and 113 Kalmar Hybrid Straddle Carriers and an annual terminal capacity of 3.6M TEUs following ongoing expansion. 

The electric straddle carriers are fitted with the latest most technically advanced lithium-ion batteries designed especially for heavy equipment, they can operate for up to 600 minutes. Additionally, the machines will be equipped with the Kalmar Collision Warning System, which improves safety by alerting operators to potential collision risks using a combination of visual and audible alarms.

Patrick Jefferson, Director of Operations, NIT: “Integrating these fully electric Kalmar straddle carriers with the Collision Warning System into our operations is a vital step in our journey to create safer and more sustainable operations.’’

Troy Thompson, Head of Sales Americas, Kalmar: “We are incredibly proud to continue our partnership with The Port of Virginia, a collaborative relationship that has thrived since 2007. Expanding their fleet to 113 Kalmar Straddle Carriers is a tremendous testament to the trust they place in our solutions. We are thrilled that our fully electric carriers and the Kalmar Collision Warning System will support them to continue to drive safe, sustainable, and profitable operations well into the future.”

Further information for the press:

Troy Thompson, Head of Sales Americas, Kalmar, troy.thompson@kalmarglobal.com 

Annelies Nentjes, Director Marketing and Communications Horizontal Transportation, Kalmar, tel. +31613239846, annelies.nentjes@kalmarglobal.com 

Kalmar (Nasdaq Helsinki: KALMAR) is moving goods in critical supply chains around the world, with the vision to be the forerunner in sustainable material handling equipment and services. The company offers a wide range of industry shaping heavy material handling equipment and services to ports and terminals, distribution centres, manufacturing and heavy logistics. Headquartered in Helsinki, Finland, Kalmar operates globally in over 120 countries and employs approximately 5,300 people. In 2025, the company’s sales totalled approximately EUR 1.7 billion. www.kalmarglobal.com 

Attachment

• Kalmar Electric Straddle Carriers

23, Place des Carmes-Déchaux – 63000 CLERMONT-FERRAND

Information about securities repurchasing program
Regulated information
Issuer social denomination: Michelin – LEI 549300SOSI58J6VIW052
Types of securities: ordinary shares – Code ISIN FR001400AJ45
Date : October 29th, 2026

Issuer Name	Issuer code	Transaction date	ISIN Code	Daily total volume (in number of actions)	Daily weighted average price of shares acquired	Platform
Compagnie Générale des Etablissements Michelin	549300SOSI58J6VIW052	29.10.2026	FR001400AJ45	212 973	30.7292 euros	Over-the-counter
Compagnie Générale des Etablissements Michelin	549300SOSI58J6VIW052	29.10.2026	FR001400AJ45	212 973	30.7292 euros	Over-the-counter
Compagnie Générale des Etablissements Michelin	549300SOSI58J6VIW052	29.10.2026	FR001400AJ45	212 973	30.7292 euros	Over-the-counter

Issuer Name	Issuer code	PSI Name	Issuer Code	Transaction date	ISIN Code	Unit Price	Currency	Quantity bought	Platform	Transaction reference number	Buyback objective
Compagnie Générale des Etablissements Michelin	549300SOSI58J6VIW052	NATIXIS	KX1WK48MPD4Y2NCUIZ63	29.10.2026	FR001400AJ45	30,7292	Euro	212 973	Over-the-counter	5309224	Cancellation
Compagnie Générale des Etablissements Michelin	549300SOSI58J6VIW052	BNP PARIBAS	R0MUWSFPU8MPRO8K5P83	29.10.2026	FR001400AJ45	30,7292	Euro	212 973	Over-the-counter	5309224	Cancellation
Compagnie Générale des Etablissements Michelin	549300SOSI58J6VIW052	SOCIETE GENERALE	O2RNE8IBXP4R0TD8PU41	29.10.2026	FR001400AJ45	30,7292	Euro	212 973	Over-the-counter	5309224	Cancellation

Attachment

• 20260813 – Disclosure of trading in own shares – October 29th, 2026

KALMAR CORPORATION, INSIDE INFORMATION, 29 OCTOBER 2026 AT 9:10 EET

Inside information: Kalmar updates its strategy and sets new performance targets for 2030 including a renewed framework for the capital allocation

The Board of Directors of Kalmar Corporation has approved an updated strategy and performance targets for the strategy period until 2030. The updated strategy shifts Kalmar’s focus towards accelerated growth and lifetime value and strengthens the company’s position as a forerunner in intelligent and sustainable heavy material handling solutions.

Kalmar’s strategic focus areas until 2030 are 1) Investing in sustainable innovations, 2) Accelerating services and customer lifetime value and 3) Driving growth.

Kalmar’s key performance targets by 2030 are:

• Sales growth exceeding 8% per annum over the cycle (previous target: 5%)
• Comparable operating profit margin of 16% by 2030 (previous target: 15% by 2028)
• Return on capital employed (ROCE) exceeding 25% by 2030 (unchanged)
• Eco portfolio accounting for more than 50% of sales by 2030 (new target)
• Services sales of EUR 800 million by 2030 (new target)
• Additional gross efficiency improvements of EUR 50 million by the end of 2030 (new target)

In addition to key performance targets, Kalmar remains committed to the near and long-term science-based emissions reduction targets with the Science Based Targets Initiative (SBTi).

Kalmar aims for a dividend payout ratio of 30–50% (unchanged). The leverage target is to have a net debt to EBITDA ratio below 2.5x (previously <2.0x). As part of its capital allocation framework, Kalmar aims to pursue targeted acquisitions that support its strategy and complement organic growth.

Kalmar’s guidance for 2026 remains unchanged: Kalmar expects its comparable operating profit margin to be above 12.5 percent in 2026.

“Over the past two years, we’ve built a strong foundation as an independent and more service focused company. Now, we are accelerating our sustainable and profitable growth with an even stronger focus on customer lifetime value. By delivering intelligent, autonomous, and data-driven sustainable solutions alongside expanded services, we empower our customers to thrive while delivering high value to our shareholders,” says Sami Niiranen, President and CEO of Kalmar.

President and CEO Sami Niiranen and other members of Kalmar’s leadership team will present the company’s updated strategy and performance targets in detail at Kalmar’s Capital Markets Day on November 2, 2026. The live webcast will begin at 1.00 p.m. EET and will include online Q&A sessions. Please register and join the webcast via the following link: https://kalmar.events.inderes.com/2026-cmd. The webcast is open to all interested parties. A recording will be available via the same link shortly after the event.

Kalmar Corporation

For more information, please contact:

Carina Geber-Teir, SVP, IR, Marketing & Communications, tel. +358 40 502 4697

About Kalmar
Kalmar (Nasdaq Helsinki: KALMAR) is moving goods in critical supply chains around the world, with the vision to be the forerunner in sustainable material handling equipment and services. The company offers a wide range of industry shaping heavy material handling equipment and services to ports and terminals, distribution centres, manufacturing and heavy logistics. Headquartered in Helsinki, Finland, Kalmar operates globally in over 120 countries and employs approximately 5,300 people. In 2025, the company’s sales totalled approximately EUR 1.7 billion. www.kalmarglobal.com 

TME Pharma Signs Binding Exclusive Negotiation Agreement with Japanese TMS Co., Ltd. 

• TME Pharma receives €150,000 for 6 months of exclusivity to negotiate a definitive agreement for worldwide rights to NOX-A12
• TMS Co., Ltd., a Japanese clinical stage biotechnology company, to establish a subsidiary (“Subsidiary”) to facilitate the financing and further clinical development of NOX-A12
• Non-binding terms negotiated as basis for further discussions. According to these terms, TME Pharma to receive the following upon signing of the definitive agreement:
   
  • Near-term payments of approximately €10M in a combination of cash and an interest in the Subsidiary (through shares and debt);
  • >€100 million in regulatory and commercial sales milestones;
  • Royalties of 8 – 10% on sales projected to peak at approximately $1 billion;
  • Sharing of any licensing fees received by Subsidiary.

Berlin, Germany, October 29, 2026, 8.15am CET – TME Pharma N.V. (Euronext Growth Paris: ALTME), a biotech-company with clinical assets for brain cancer and eye diseases, is pleased to announce a significant next step in the strategic options for its leading oncology asset, NOX-A12 (olaptesed pegol).

Following a thorough evaluation and discussions with potential partners, TME Pharma has selected TMS Co., Ltd. (“TMS”) as its preferred partner to advance the further development and commercialization of NOX-A12 for glioblastoma.

Key Terms of the Agreement
TME Pharma and TMS have entered into a binding exclusive negotiation agreement and a non-binding Term Sheet with the following key terms:        

• Exclusivity: TMS Co. will pay a non-refundable fee of €150,000 for a 6-month exclusive negotiation period may be extended with further payments. During this time, TME will neither solicit nor accept offers from third parties and will refrain from any discussions or negotiations with third parties with respect to licensing, developing and commercializing NOX-A12 with any third parties other than TMS and its Subsidiary.
• Non-binding terms subject to further negotiation for exclusive access to NOX-A12 include:
  • Upfront and near-term payments to TME Pharma of approximately €10M in a combination of cash and an interest in the Subsidiary (through shares and debt);
  • >€100 million in regulatory and commercial sales milestones;
  • Royalties of 8 – 10% on sales projected by TME Pharma to peak at approximately $1 billion;
  • Percentage of any sub-licensing fees received by Subsidiary;
  • Subsidiary to lead the financing process.
  • Further development of NOX-A12 with support of TME Pharma as partner and minority shareholder of subsidiary.

Timeline and Financing of the Phase 2 Study        
TME Pharma and TMS Co agreed on a clear roadmap to finalize the definitive agreement which is a key step towards enabling the rapid resumption of the NOX-A12 Phase 2 GLORIA study.

The partnership comes amid a recovery in biopharma capital markets and dealmaking. According to J.P. Morgan¹, biopharma licensing reached $166.7 billion in announced deal value and venture funding totaled $16.3 billion in the first half of 2026, with capital increasingly directed toward later-stage clinical programs.
TME Pharma and TMS Co believe that this environment is favorable for the planned financing through TMS’ Subsidiary and intend to leverage the strong and positive momentum for further clinical development to move as quickly as possible to the rollout of the approved Phase 2 GLORIA study with NOX-A12.

NOX-A12 has received Fast Track designation from the U.S. FDA and Orphan Drug designations in the U.S. and Europe. Compelling clinical results from the GLORIA study have recently been published in Nature Communications.

“By choosing TMS Co. Ltd., we believe we have found an excellent partner to unlock the full potential of NOX-A12 and bring value creation back on track by resuming clinical development for glioblastoma. Once the final agreement is successfully concluded and the TMS Subsidiary is ready to restart the GLORIA trial, TME Pharma’s shareholders can expect a cash inflow that, thanks to the company’s low operating costs and extended debt maturity, will significantly extend its financial horizon. Furthermore, substantial milestone and royalty payments can be expected if the program is a success, which we consider likely if the GLORIA study shows results that are as strong as the statistically significant survival data we have already observed and that were published in Nature Communications in April 2026. I believe that this alliance will be able to unlock tremendous potential for TME Pharma shareholders – our assessment using industry standard risk-adjusted valuation models (rNPV) for Phase 2 oncology assets indicates the substantial value of this transaction.”, Diede van den Ouden, CEO, said.

For more information, please contact:
TME Pharma N.V.
Diede van den Ouden, CEO
ir@tmepharma.com
www.tmepharma.com

About TME Pharma

TME Pharma is a biotechnology company with two assets with potential to be developed into novel therapies for cancer and eye diseases. The Company’s lead compounds have been designed to act on the tumor microenvironment (TME) and the cancer immunity cycle by breaking tumor protection barriers against the immune system and blocking tumor repair. The Company’s two lead assets are:

• NOX-A12 (olaptesed pegol, an anti-CXCL12 L-RNA aptamer), which has been studied (GLORIA Phase 1/2 clinical trial) in newly-diagnosed brain cancer patients who will not benefit clinically from standard chemotherapy. The US FDA and the German BfArM have approved the design of a randomized Phase 2 trial in glioblastoma, and TME Pharma was awarded Fast Track Designation by the FDA for NOX-A12 in combination with radiotherapy and bevacizumab for use in the treatment of the aggressive adult brain cancer, glioblastoma. NOX-A12 in combination with radiotherapy had also previously received orphan drug designation (ODD) for glioblastoma in the United States and glioma in Europe.
• NOX-E36 (emapticap pegol, L-RNA aptamer inhibiting CCL2 and related chemokines), for ophthalmic diseases with a high need for well-tolerated therapies with anti-fibrotic effect.

The Company is currently seeking opportunities to secure the financial resources to unlock the value of NOX-A12 and NOX-E36. These steps include:

• Finalizing the partnership with TMS Co., Ltd. For NOX-A12
• Raising funds from alternative sources to secure longer financial visibility and to minimize dilution for shareholders
• Seeking partners for NOX-E36, for example through licensing deals
• Pursuing stable, cash-generating business opportunities to achieve positive operational cash flow for the Company
• Leveraging tax loss carry forwards

About the GLORIA Study
The GLORIA (NCT04121455) ‘ready to go’-study is TME Pharma’s dose-escalation, Phase 1/2 study of NOX-A12 in combination with radiotherapy and bevacizumab in first-line partially resected or unresected glioblastoma (brain cancer) patients with unmethylated MGMT promoter (resistant to standard chemotherapy).

About the OPTIMUS Study
OPTIMUS (NCT04901741) is TME Pharma’s planned open-label two-arm Phase 2 study of NOX-A12 combined with pembrolizumab and nanoliposomal irinotecan/5-FU/leucovorin or gemcitabine/nab-paclitaxel in microsatellite-stable metastatic pancreatic cancer patients.

Further information can be found at: www.tmepharma.com.

Disclaimer
Translations of any press release into languages other than English are intended solely as a convenience to the non-English-reading audience. The company has attempted to provide an accurate translation of the original text in English, but due to the nuances in translating into another language, slight differences may exist. This press release includes certain disclosures that contain “forward-looking statements.” Forward-looking statements are based on TME Pharma’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, the risks inherent in oncology drug development, including clinical trials and the timing of and TME Pharma’s ability to obtain regulatory approvals for NOX-A12 as well as any other drug candidates. Forward-looking statements contained in this announcement are made as of this date, and TME Pharma undertakes no duty to update such information except as required under applicable law.

---

¹ https://www.jpmorgan.com/content/dam/jpmorgan/documents/cb/insights/outlook/jpm-biopharma-deck-q2-2026-2.pdf

Attachment

• TME Pharma Signs Binding Exclusive Negotiation Agreement with Japanese TMS Co., Ltd.